Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;9(4):1515-1519.
doi: 10.3892/ol.2015.2888. Epub 2015 Jan 23.

Animal models for bladder cancer: The model establishment and evaluation (Review)

Affiliations

Animal models for bladder cancer: The model establishment and evaluation (Review)

Ning Zhang et al. Oncol Lett. 2015 Apr.

Abstract

Bladder cancer is the most common type of tumor in the urogenital system. Approximately 75% of patients with bladder cancer present with non-muscle-invasive cancer, which is generally treated by transurethral resection and intravesical chemotherapy. In spite of different therapeutic options, there remains a very variable risk of recurrence and progression. Novel therapeutic methods of treating bladder cancer are urgently required. The exploration and preclinical evaluation of new treatments requires an animal tumor model that mimics the human counterpart. Animal models are key in bladder cancer research and provide a bridge to the clinic. Various animal bladder cancer models have been described to date, but the tumor take rate is reported to be 30-100%. Establishment of reliable, simple, practicable and reproducible animal models remains an ongoing challenge. The present review summarizes the latest developments with regard to the establishment of animal models and tumor evaluation.

Keywords: animal models; bladder cancer; heterotopic models; living tissue grafting; orthotopic models.

PubMed Disclaimer

References

    1. Burger M, Catto J, Dalbagni GW, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–241. doi: 10.1016/j.eururo.2012.07.033. - DOI - PubMed
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403. doi: 10.1016/j.ejca.2012.12.027. - DOI - PubMed
    1. Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumors. 7th edition. Wiley-Blackwell; Hoboken, NJ, USA: 2009. pp. 262–265.
    1. Dalbagni G. Bladder cancer restaging TUR reduces recurrence and progression risk. Nat Rev Urol. 2010;7:649–650. doi: 10.1038/nrurol.2010.189. - DOI - PubMed
    1. Chan E, Patel A, Heston W, Larchian W. Mouse orthotopic models for bladder cancer research. BJU Int. 2009;104:1286–1291. doi: 10.1111/j.1464-410X.2009.08577.x. - DOI - PubMed

LinkOut - more resources